News
News
OPEN CALL
Are you a researcher developing a new vaccine and need support?
Apply now >>
TRANSVAC2 is now offering FREE services as part of ISIDORe!
Coming soon
Training programme in advanced vaccinology
TRANSVAC Academy has officially started! Check all courses available and submit your application today! Advance your vaccinology training with expert-led courses!
Open call
Training programme in advanced vaccinology
TRANSVAC Academy has officially started! Check all courses available and submit your application today! Advance your vaccinology training with expert-led courses!
TRANSVAC Academy
is dedicated to fostering the next generation of vaccine researchers, by providing a comprehensive state-of-the-art training programme.
Open call | Apply until 21 October 2024!
OPEN CALL for Applications
TRANSVAC2, renowned for high-quality vaccine development support, is thrilled to offer FREE services through the ISIDORe network. These are the focus areas for this call:
Adjuvant and Formulation Expertise (VFI) >>
Vaccine technologies, process development & production (iBet) >>
Eligible projects must target pathogens listed in the ISIDORe Open Calls.
Deadline: July 29th.
Training: Open Call
Submit your application by Dec 31st
OPEN CALL for TRAININGS
Training modules on fundamental and advanced knowledge on a wide-range of vaccine R&D topics
Submit your application for Vaccinology Trainings. We have 3 courses now open for applications!
Services at all stages
of the Vaccine R&D Pipeline
OPEN CALL for SERVICES
Submit your application for Vaccine Development Services
TRANSVAC2 TNA CALL FOR PROPOSALS
With the pandemic still ongoing, TRANSVAC2 is renewing its commitment to supporting academic and commercial vaccine developers through a new call for proposals dedicated to SARS-CoV-2 / COVID-19, with a special emphasis on variants of concern. Other project proposals will also be considered.
You may apply for free-of-charge TNA vaccine development services to advance your research in one of the following main areas:
Technology
Antigen screening, optimization, expression, and production
Adjuvant formulation and characterization (incl. liposomal, mucosal, and parenteral adjuvants)
Analytical services offer diverse structural and cellular assays (Now including Luminex potency assay!)
GLP/GMP vaccine production using bacterial, yeast, plant, insect, and mammalian platforms
Immunocorrelates/ systems biology
Includes sequencing, cytometry and various -omics services
Statistical analysis and mathematical modelling
Animal models
Services offer a wide range of species and validated disease models, from rodents to NHPs
Clinical trial and regulatory support services
We highly encourage all applicants to request regulatory support alongside scientific technical services, as early assessment of regulatory requirements may prevent unnecessary project delays, reduce costs and ensure adherence to legal requirements.
Service availability is dependent on budgetary, and timeline constrains and thus subject to change at later stages of the application process. Applicants should contact service providers before submission.
z
DEADLINE
This call for proposals will remain open until May 31st, 2022. Your proposal will be evaluated, selected and implemented according to the selection process.
APPLICATION
Applicants can be affiliated to an organization (public or private) located in the EU, an associated country or any other country. For more information about TRANSVAC2 TNA Programme, including the conditions for access & eligibility, please refer to Apply now.
To apply, please make sure that you use the latest TNA Application Form linked and carefully read the form and help text.
Please note that an organization can submit several applications led by different Users.
For any further question, please contact TRANSVAC2 Coordinating team (transvacinfo@euvaccine.eu).
Support to development of vaccines against COVID19
“Rapid progress towards the development of potent vaccines can only happen through concerted and coordinated efforts around Europe and the world – and TRANSVAC2 is well positioned to facilitate such efforts.” - Dr. Hilde Depraetere, TRANSVAC2 Coordinator
To support of the global effort to accelerate the development of a vaccine against Sars-CoV-2, TRANSVAC2 launched in April 2020 a specific call for applications focused on the development of novel COVID-19 vaccines.
Consequently, a variety of TRANSVAC2 services, from antigen discovery to preclinical and clinical trial support (In total 31 services), will be delivered to help eight awarded research groups from SMEs and public institutions to speed-up the COVID-19 vaccine development pipeline.
This initiative is fully supported by the European Commission which provides, additional top-up funds worth EUR 4 millions.
Excerpt adapted from https://ec.europa.eu/research/infocentre/article_en.cfm?artid=49836